For research use only. Not for therapeutic Use.
Vociprotafib (RMC-4630) is a SHP2 inhibitor, a phosphatase whose inhibition blocks activation of the RAS-RAF-MEK-ERK signaling pathway. Vociprotafib has antitumor activity[1][2].
| Catalog Number | I045270 |
| CAS Number | 2172652-48-9 |
| Synonyms | [6-(2-amino-3-chloropyridin-4-yl)sulfanyl-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl]methanol |
| Molecular Formula | C20H27ClN6O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C20H27ClN6O2S/c1-11-19(30-14-3-6-24-17(23)15(14)21)26-13(9-28)18(25-11)27-7-4-20(5-8-27)10-29-12(2)16(20)22/h3,6,12,16,28H,4-5,7-10,22H2,1-2H3,(H2,23,24)/t12-,16+/m0/s1 |
| InChIKey | HISJAYUQVHMWTA-BLLLJJGKSA-N |
| SMILES | CC1C(C2(CCN(CC2)C3=NC(=C(N=C3CO)SC4=C(C(=NC=C4)N)Cl)C)CO1)N |
| Reference | [1]. WO2018013597 [2]. Smith J A, et al. SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway. Cancer Research, 2020, 80(16_Supplement): 1943-1943. |
